Abiraterone, CYP17 inhibitor Abiraterone (CB-7598)


Catalog No. size PriceQuantity
M60031-2D 10 mM in DMSO (0.573 mL) $79
M60031-2S 2 mg solid $79
M60031-10S 10mg solid $312

Description

Product Information
Molecular Weight: 349.51
Formula: C24H31NO
Purity: ≥98%
CAS#: 154229-19-3
Solubility: DMSO up to 20mM
Chemical Name: (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.



Biological Activity:


Abiraterone is the first-in-class potent and selective CYP17 (cytochrome P450 17alpha-hydroxylase-17,20-lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration-resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication, the structures of cytochrome P450 17A1 with abiraterone was released. A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway.


How to Use:


In vitro: Abiraterone is typically used at 1 ¦ÌM concentration in vitro.

In vivo: Abiraterone acetate (pro-drug) was dosed to mice and rats at 50 mg/kg orally once per day.


Reference:


  • 1. Jarman M, et al. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. (1998) J Med Chem. 41(27):5375-81.
  • 2. Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. (2008) J Clin Oncol. 26(28):4563-71.
  • 3. Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. (2009) J Clin Oncol. 27(23):3742-8.
  • 4.  de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. (2011) N Engl J Med. 364(21):1995-2005.
  • 5.  DeVore NM, et al. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. (2012) Nature. 482(7383):116-9.


Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed